Medical Technology Venture Partners

Radu Cautis serves as Partner & Managing Director and leads the investment process. He built his operating career at Gambro, scaling its Asia device business and leading strategic marketing, before moving into venture. He is supported by a partnership of former CEOs, including Thomas Glanzmann (ex-Gambro) and Peter Loescher (ex-Siemens), who engage directly with portfolio companies on clinical and regulatory strategy.

Sourcing runs through the personal clinical networks of its operating partners and venture partners. Christine Winoto and Regis Kelly bring direct access to the UCSF medtech pipeline through their leadership of the Rosenman Institute and QB3 program. The firm does not advertise standard associate-led sourcing or a broad GP conference circuit; instead, its partners identify device entrepreneurs during clinical-fellow rotations and academic prototyping labs.

The firm operates as an asset manager deploying private capital into medical technology companies, but it does not disclose a formal fund structure with vintage years. Its partnership composition — heavy on former operators rather than institutional fund managers — and the absence of a publicly stated AUM suggest a more flexible capital base than a conventional blind-pool venture fund.

The portfolio page lists only direct company investments. There is no public record of Medical Technology Venture Partners making LP commitments into external venture funds. Its model is built on taking board-level, operator-intensive positions in individual medtech startups.

The firm's exclusive focus on medical devices and diagnostics means it does not invest in biopharma therapeutics, healthcare services, or pure health IT plays. Its portfolio of neuromodulation implants, surgical tools, and radiation oncology hardware reflects a specific avoidance of drug-development binary risk and a preference for 510(k)/PMA regulatory pathways.

Javad Seyedzadeh brings 30 years of quality assurance and regulatory affairs experience from Gambro, Toshiba, Bayer, and Siemens directly into the investment process. His presence means regulatory pathway feasibility is evaluated during diligence rather than outsourced to consultants, which is atypical for an early-stage venture firm.

Three exits are listed publicly. Ulthera, an aesthetic ultrasound company led by current EIR Mathew Likens, was acquired by Merz Pharma for $600 million in 2014. An umbilical catheter protection device was sold to Laborie, and an arthroscopic tissue removal tool was acquired by Zimmer. The firm does not disclose return multiples.